Title : Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.

Pub. Date : 2017 Mar

PMID : 27489245






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Vorapaxar is a novel antiplatelet agent that targets the platelet protease-activated receptor 1 and inhibits thrombin-induced platelet activation. vorapaxar coagulation factor II, thrombin Homo sapiens
2 New data from the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 P)-TIMI 50 trial MI cohort demonstrate that the subgroup of patients with T2DM exhibits increased benefit from vorapaxar use compared with non-T2DM patients. vorapaxar coagulation factor II, thrombin Homo sapiens